Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.
Narita T, Inagaki A, Kobayashi T, Kuroda Y, Fukushima T, Nezu M, Fuchida S, Sakai H, Sekiguchi N, Sugiura I, Maeda Y, Takamatsu H, Tsukamoto N, Maruyama D, Kubota Y, Kojima M, Sunami K, Ono T, Ri M, Tobinai K, Iida S. Narita T, et al. Among authors: takamatsu h. Blood Cancer J. 2015 Feb 27;5(2):e285. doi: 10.1038/bcj.2015.6. Blood Cancer J. 2015. PMID: 25723856 Free PMC article. No abstract available.
Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
Takamatsu H, Ogawa Y, Kobayashi N, Obata K, Narisawa T, Nakayama K, Munemoto S, Aoki G, Ohata K, Kumano Y, Ozaki J, Murata R, Kondo Y, Terasaki Y, Kurokawa T, Miyamoto T, Shimizu N, Fukushima T, Yoshida A, Ueda T, Yoshida T, Nakao S. Takamatsu H, et al. Exp Hematol. 2013 Oct;41(10):894-902. doi: 10.1016/j.exphem.2013.05.004. Epub 2013 May 30. Exp Hematol. 2013. PMID: 23727584 Free article.
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.
Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Shimada K, Ito S, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Kimura G, Umemura S, Ura N, Hayashi K, Odawara M, Tanahashi N, Ishimitsu T, Kashihara N, Morita S, Teramukai S; COLM Investigators. Ogihara T, et al. J Hypertens. 2014 Oct;32(10):2054-63; discussiom 2063. doi: 10.1097/HJH.0000000000000281. J Hypertens. 2014. PMID: 24999799 Free PMC article. Clinical Trial.
Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Kawamura K, Takamatsu H, Ikeda T, Komatsu T, Aotsuka N, Amano I, Yamamoto G, Watanabe K, Ohno Y, Matsue K, Kouzai Y, Tsukada N, Ishiyama K, Anzai N, Kato K, Suzuki R, Sunami K, Kanda Y. Kawamura K, et al. Among authors: takamatsu h. Biol Blood Marrow Transplant. 2015 Jul;21(7):1291-8. doi: 10.1016/j.bbmt.2015.02.015. Epub 2015 Feb 21. Biol Blood Marrow Transplant. 2015. PMID: 25708214 Free article.
Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Takamatsu H, Yamashita T, Kurahashi S, Saitoh T, Kondo T, Maeda T, Nakazawa H, Murata M, Narita T, Kuroda J, Hashimoto H, Kawamura K, Miyamoto T, Honda S, Ichinohe T, Atsuta Y, Sunami K. Takamatsu H, et al. Biol Blood Marrow Transplant. 2019 Mar;25(3):474-479. doi: 10.1016/j.bbmt.2018.11.003. Epub 2018 Nov 10. Biol Blood Marrow Transplant. 2019. PMID: 30423479 Free article.
Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society.
Abe Y, Sunami K, Yamashita T, Ueda M, Takamatsu H, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Matsue K. Abe Y, et al. Among authors: takamatsu h. Oncotarget. 2019 Jan 15;10(5):595-605. doi: 10.18632/oncotarget.26562. eCollection 2019 Jan 15. Oncotarget. 2019. PMID: 30728910 Free PMC article.
Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.
Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A. Mizuno S, et al. Among authors: takamatsu h. Bone Marrow Transplant. 2019 Oct;54(10):1595-1604. doi: 10.1038/s41409-019-0478-4. Epub 2019 Feb 19. Bone Marrow Transplant. 2019. PMID: 30783208
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K. Sunami K, et al. Among authors: takamatsu h, takamatsu y. Int J Clin Oncol. 2019 Aug;24(8):966-975. doi: 10.1007/s10147-019-01436-8. Epub 2019 Apr 1. Int J Clin Oncol. 2019. PMID: 30937622 Clinical Trial.
596 results